London, 04 March 2015: TechNavio, the independent tech-focused global research firm, has published a report on the Global Travel Vaccines Market 2015-2019, which is expected to post a CAGR of 7.78 percent during the forecast period of 2014-2019.
Increased prevalence of various infectious diseases encourages the use of vaccines worldwide. Advances in technology are resulting in the development of innovative vaccines such as dendritic cell vaccines, DNA vaccines, T-cell receptor peptide vaccines, and recombinant vector vaccines.
“Vaccine manufacturers are shifting their bases to developing countries to utilize the favorable business conditions in these countries,” says Faisal Ghaus, Vice President of TechNavio.
“Global players are targeting countries such as India and China as vaccine development hubs because of the availability of skilled manpower, excellent manufacturing capabilities, and low manufacturing costs.”
Key Market Drivers
- Increase in Demand among Travelers
- Increase in Prevalence of Infectious Diseases
- Increase in Awareness
- Emergence of Resistant Strains
Key Market Trends
- Public-Private Initiatives
- Combination Vaccines
- Emerging Markets
Key Market Vendors
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Sanofi
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
